Stabilization of Microtubule-Unbound Tau via Tau Phosphorylation at Ser262/356 by Par-1/MARK Contributes to Augmentation of AD-Related Phosphorylation and Aβ42-Induced Tau Toxicity

PLoS Genetics

Volumn 12, Issue 3, 2016, Pages

  Ando, Kanae ^a,b   Maruko Otake, Akiko ^b   Ohtake, Yosuke ^b   Hayashishita, Motoki ^a   Sekiya, Michiko ^c   Iijima, Koichi M ^c  

^a TOKYO METROPOLITAN UNIVERSITY   (Japan)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; GLYCOGEN SYNTHASE KINASE 3; MICROTUBULE AFFINITY REGULATING KINASE; PHOSPHOTRANSFERASE; PROTEINASE ACTIVATED RECEPTOR 1; SERINE; TAU PROTEIN; THREONINE; UNCLASSIFIED DRUG; GLYCOGEN SYNTHASE KINASE 3BETA; TUBULIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOSOL; DRUG TARGETING; FEMALE; GENE SILENCING; HUMAN; MALE; MICROTUBULE; NEUROPATHOLOGY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN TARGETING; TAUOPATHY; TRANSGENIC DROSOPHILA; ANIMAL; DISEASE MODEL; DROSOPHILA; GENETICS; HIPPOCAMPUS; METABOLISM; NERVE CELL; PATHOLOGY; PHOSPHORYLATION; TRANSGENIC ANIMAL;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANIMALS, GENETICALLY MODIFIED; DISEASE MODELS, ANIMAL; DROSOPHILA; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; HIPPOCAMPUS; HUMANS; MICROTUBULES; NEURONS; PHOSPHORYLATION; RECEPTOR, PAR-1; TAU PROTEINS; TUBULIN;

EID: 84962388453     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1005917     Document Type: Article

References (116)

1. Hardy J, Selkoe DJ, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353–6. 12130773
2. Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ, Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A. 2011;108(14):5819–24. doi: 10.1073/pnas.101703310821421841
3. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001;293(5534):1487–91. 11520987
4. Gotz J, Chen F, van Dorpe J, Nitsch RM, Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 2001;293(5534):1491–5. 11520988
5. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM, Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004;43(3):321–32. 15294141
6. Selkoe DJ, Resolving controversies on the path to Alzheimer's therapeutics. Nat Med. 2011;17(9):1060–5. Epub 2011/09/09. doi: 10.1038/nm.246021900936
7. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316(5825):750–4. 17478722
8. Spires-Jones TL, Hyman BT, The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron. 2014;82(4):756–71. doi: 10.1016/j.neuron.2014.05.00424853936
9. Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM, Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol Aging. 2005;26(5):645–54. 15708439
10. Chabrier MA, Blurton-Jones M, Agazaryan AA, Nerhus JL, Martinez-Coria H, LaFerla FM, Soluble abeta promotes wild-type tau pathology in vivo. J Neurosci. 2012;32(48):17345–50. doi: 10.1523/JNEUROSCI.0172-12.201223197725
11. Cowan CM, Mudher A, Are tau aggregates toxic or protective in tauopathies?Frontiers in neurology. 2013;4:114. doi: 10.3389/fneur.2013.0011423964266
12. Sahara N, Maeda S, Takashima A, Tau oligomerization: a role for tau aggregation intermediates linked to neurodegeneration. Curr Alzheimer Res. 2008;5(6):591–8. 19075586
13. Kuchibhotla KV, Wegmann S, Kopeikina KJ, Hawkes J, Rudinskiy N, Andermann ML, et al. Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo. Proc Natl Acad Sci U S A. 2014;111(1):510–4. doi: 10.1073/pnas.131880711124368848
14. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309(5733):476–81. 16020737
15. von Bergen M, Friedhoff P, Biernat J, Heberle J, Mandelkow EM, Mandelkow E, Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc Natl Acad Sci U S A. 2000;97(10):5129–34. 10805776
16. Perez M, Santa-Maria I, Tortosa E, Cuadros R, Del Valle M, Hernandez F, et al. The role of the VQIVYK peptide in tau protein phosphorylation. J Neurochem. 2007;103(4):1447–60. 17680993
17. Karagoz GE, Duarte AM, Akoury E, Ippel H, Biernat J, Moran Luengo T, et al. Hsp90-Tau complex reveals molecular basis for specificity in chaperone action. Cell. 2014;156(5):963–74. doi: 10.1016/j.cell.2014.01.03724581495
18. Fischer D, Mukrasch MD, Biernat J, Bibow S, Blackledge M, Griesinger C, et al. Conformational changes specific for pseudophosphorylation at serine 262 selectively impair binding of tau to microtubules. Biochemistry. 2009;48(42):10047–55. doi: 10.1021/bi901090m19769346
19. Thies E, Mandelkow EM, Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. J Neurosci. 2007;27(11):2896–907. Epub 2007/03/16. 17360912
20. Dickey CA, Kamal A, Lundgren K, Klosak N, Bailey RM, Dunmore J, et al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest. 2007;117(3):648–58. Epub 2007/02/17. 17304350
21. Hasegawa M, Morishima-Kawashima M, Takio K, Suzuki M, Titani K, Ihara Y, Protein sequence and mass spectrometric analyses of tau in the Alzheimer's disease brain. J Biol Chem. 1992;267(24):17047–54. 1512244
22. Hanger DP, Betts JC, Loviny TL, Blackstock WP, Anderton BH, New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J Neurochem. 1998;71(6):2465–76. Epub 1998/12/01. 9832145
23. Hanger DP, Brion JP, Gallo JM, Cairns NJ, Luthert PJ, Anderton BH, Tau in Alzheimer's disease and Down's syndrome is insoluble and abnormally phosphorylated. Biochem J. 1991;275 (Pt 1):99–104. 1826835
24. Morishima-Kawashima M, Hasegawa M, Takio K, Suzuki M, Yoshida H, Titani K, et al. Proline-directed and non-proline-directed phosphorylation of PHF-tau. J Biol Chem. 1995;270(2):823–9. 7822317
25. Feuillette S, Miguel L, Frebourg T, Campion D, Lecourtois M, Drosophila models of human tauopathies indicate that Tau protein toxicity in vivo is mediated by soluble cytosolic phosphorylated forms of the protein. J Neurochem. 2010;113(4):895–903. doi: 10.1111/j.1471-4159.2010.06663.x20193038
26. Chatterjee S, Sang TK, Lawless GM, Jackson GR, Dissociation of tau toxicity and phosphorylation: role of GSK-3beta, MARK and Cdk5 in a Drosophila model. Hum Mol Genet. 2009;18(1):164–77. doi: 10.1093/hmg/ddn32618930955
27. Planel E, Krishnamurthy P, Miyasaka T, Liu L, Herman M, Kumar A, et al. Anesthesia-induced hyperphosphorylation detaches 3-repeat tau from microtubules without affecting their stability in vivo. J Neurosci. 2008;28(48):12798–807. doi: 10.1523/JNEUROSCI.4101-08.200819036972
28. Miyasaka T, Sato S, Tatebayashi Y, Takashima A, Microtubule destruction induces tau liberation and its subsequent phosphorylation. FEBS Lett. 2010;584(14):3227–32. doi: 10.1016/j.febslet.2010.06.01420561519
29. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009;11(7):909–13. doi: 10.1038/ncb190119503072
30. Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VM, Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. J Neurosci. 2013;33(3):1024–37. doi: 10.1523/JNEUROSCI.2642-12.201323325240
31. Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron. 2010;68(6):1067–81. doi: 10.1016/j.neuron.2010.11.03021172610
32. Yamada K, Holth JK, Liao F, Stewart FR, Mahan TE, Jiang H, et al. Neuronal activity regulates extracellular tau in vivo. The Journal of experimental medicine. 2014;211(3):387–93. doi: 10.1084/jem.2013168524534188
33. Saman S, Kim W, Raya M, Visnick Y, Miro S, Saman S, et al. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem. 2012;287(6):3842–9. doi: 10.1074/jbc.M111.27706122057275
34. Frost B, Jacks RL, Diamond MI, Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem. 2009;284(19):12845–52. doi: 10.1074/jbc.M80875920019282288
35. Busciglio J, Lorenzo A, Yeh J, Yankner BA, beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron. 1995;14(4):879–88. 7718249
36. Ferreira A, Lu Q, Orecchio L, Kosik KS, Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar A beta. Mol Cell Neurosci. 1997;9(3):220–34. 9245504
37. Takashima A, Honda T, Yasutake K, Michel G, Murayama O, Murayama M, et al. Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25–35) enhances phosphorylation of tau in hippocampal neurons. Neurosci Res. 1998;31(4):317–23. 9809590
38. Ma QL, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ, et al. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci. 2009;29(28):9078–89. doi: 10.1523/JNEUROSCI.1071-09.200919605645
39. Zempel H, Thies E, Mandelkow E, Mandelkow EM, Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neurosci. 2010;30(36):11938–50. Epub 2010/09/10. doi: 10.1523/JNEUROSCI.2357-10.201020826658
40. De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN, et al. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol Aging. 2008;29(9):1334–47. 17403556
41. Folwell J, Cowan CM, Ubhi KK, Shiabh H, Newman TA, Shepherd D, et al. Abeta exacerbates the neuronal dysfunction caused by human tau expression in a Drosophila model of Alzheimer's disease. Exp Neurol. 2010;223(2):401–9. doi: 10.1016/j.expneurol.2009.09.01419782075
42. Gong CX, Liu F, Grundke-Iqbal I, Iqbal K, Post-translational modifications of tau protein in Alzheimer's disease. J Neural Transm. 2005;112(6):813–38. 15517432
43. Ma QL, Lim GP, Harris-White ME, Yang F, Ambegaokar SS, Ubeda OJ, et al. Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro. J Neurosci Res. 2006;83(3):374–84. Epub 2005/12/31. 16385556
44. Sofola O, Kerr F, Rogers I, Killick R, Augustin H, Gandy C, et al. Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease. PLoS Genet. 2010;6(9). Epub 2010/09/09.
45. Yu W, Polepalli J, Wagh D, Rajadas J, Malenka R, Lu B, A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Abeta on synapses and dendritic spines. Hum Mol Genet. 2012;21(6):1384–90. doi: 10.1093/hmg/ddr57622156579
46. Hernandez F, Gomez de Barreda E, Fuster-Matanzo A, Lucas JJ, Avila J, GSK3: a possible link between beta amyloid peptide and tau protein. Exp Neurol. 2010;223(2):322–5. doi: 10.1016/j.expneurol.2009.09.01119782073
47. Ishiguro K, Shiratsuchi A, Sato S, Omori A, Arioka M, Kobayashi S, et al. Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments. FEBS Lett. 1993;325(3):167–72. 7686508
48. Sperber BR, Leight S, Goedert M, Lee VM, Glycogen synthase kinase-3 beta phosphorylates tau protein at multiple sites in intact cells. Neurosci Lett. 1995;197(2):149–53. 8552282
49. Hanger DP, Byers HL, Wray S, Leung KY, Saxton MJ, Seereeram A, et al. Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J Biol Chem. 2007;282(32):23645–54. 17562708
50. Drewes G, Ebneth A, Preuss U, Mandelkow EM, Mandelkow E, MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell. 1997;89(2):297–308. 9108484
51. Biernat J, Gustke N, Drewes G, Mandelkow EM, Mandelkow E, Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron. 1993;11(1):153–63. 8393323
52. Lovestone S, Hartley CL, Pearce J, Anderton BH, Phosphorylation of tau by glycogen synthase kinase-3 beta in intact mammalian cells: the effects on the organization and stability of microtubules. Neuroscience. 1996;73(4):1145–57. 8809831
53. Nishimura I, Yang Y, Lu B, PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell. 2004;116(5):671–82. 15006350
54. Steinhilb ML, Dias-Santagata D, Mulkearns EE, Shulman JM, Biernat J, Mandelkow EM, et al. S/P and T/P phosphorylation is critical for tau neurotoxicity in Drosophila. J Neurosci Res. 2007;85(6):1271–8. 17335084
55. Papanikolopoulou K, Skoulakis EM, Temporally distinct phosphorylations differentiate Tau-dependent learning deficits and premature mortality in Drosophila. Hum Mol Genet. 2015;24(7):2065–77. doi: 10.1093/hmg/ddu72625524708
56. Fulga TA, Elson-Schwab I, Khurana V, Steinhilb ML, Spires TL, Hyman BT, et al. Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nat Cell Biol. 2007;9(2):139–48. 17187063
57. Mairet-Coello G, Courchet J, Pieraut S, Courchet V, Maximov A, Polleux F, The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Abeta oligomers through Tau phosphorylation. Neuron. 2013;78(1):94–108. doi: 10.1016/j.neuron.2013.02.00323583109
58. Iijima K, Gatt A, Iijima-Ando K, Tau Ser262 phosphorylation is critical for Abeta42-induced tau toxicity in a transgenic Drosophila model of Alzheimer's disease. Hum Mol Genet. 2010;19(15):2947–57. Epub 2010/05/15. doi: 10.1093/hmg/ddq20020466736
59. Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, et al. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science. 2001;293(5530):711–4. 11408621
60. Mudher A, Shepherd D, Newman TA, Mildren P, Jukes JP, Squire A, et al. GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol Psychiatry. 2004;9(5):522–30. Epub 2004/03/03. 14993907
61. Jackson GR, Wiedau-Pazos M, Sang TK, Wagle N, Brown CA, Massachi S, et al. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron. 2002;34(4):509–19. 12062036
62. Grammenoudi S, Kosmidis S, Skoulakis EM, Cell type-specific processing of human Tau proteins in Drosophila. FEBS Lett. 2006;580(19):4602–6. 16875690
63. Iijima-Ando K, Sekiya M, Maruko-Otake A, Ohtake Y, Suzuki E, Lu B, et al. Loss of Axonal Mitochondria Promotes Tau-Mediated Neurodegeneration and Alzheimer's Disease-Related Tau Phosphorylation Via PAR-1. PLoS Genet. 2012;8(8):e1002918. Epub 2012/09/07. doi: 10.1371/journal.pgen.100291822952452
64. Iijima K, Liu HP, Chiang AS, Hearn SA, Konsolaki M, Zhong Y, Dissecting the pathological effects of human Abeta40 and Abeta42 in Drosophila: a potential model for Alzheimer's disease. Proc Natl Acad Sci U S A. 2004;101(17):6623–8. 15069204
65. Lee VM, Brunden KR, Hutton M, Trojanowski JQ, Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb Perspect Med. 2011;1(1):a006437. doi: 10.1101/cshperspect.a00643722229117
66. Ballatore C, Lee VM, Trojanowski JQ, Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci. 2007;8(9):663–72. 17684513
67. Pianu B, Lefort R, Thuiliere L, Tabourier E, Bartolini F, The Abeta(1)(-)(4)(2) peptide regulates microtubule stability independently of tau. J Cell Sci. 2014;127(Pt 5):1117–27. doi: 10.1242/jcs.14375024424028
68. Hempen B, Brion JP, Reduction of acetylated alpha-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer's disease. J Neuropathol Exp Neurol. 1996;55(9):964–72. 8800092
69. King ME, Kan HM, Baas PW, Erisir A, Glabe CG, Bloom GS, Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. J Cell Biol. 2006;175(4):541–6. 17101697
70. McDonald JA, Khodyakova A, Aranjuez G, Dudley C, Montell DJ, PAR-1 kinase regulates epithelial detachment and directional protrusion of migrating border cells. Curr Biol. 2008;18(21):1659–67. Epub 2008/11/04. doi: 10.1016/j.cub.2008.09.04118976916
71. Kosmidis S, Grammenoudi S, Papanikolopoulou K, Skoulakis EM, Differential effects of Tau on the integrity and function of neurons essential for learning in Drosophila. J Neurosci. 2010;30(2):464–77. Epub 2010/01/15. doi: 10.1523/JNEUROSCI.1490-09.201020071510
72. Mershin A, Pavlopoulos E, Fitch O, Braden BC, Nanopoulos DV, Skoulakis EM, Learning and memory deficits upon TAU accumulation in Drosophila mushroom body neurons. Learn Mem. 2004;11(3):277–87. Epub 2004/06/01. 15169857
73. Papanikolopoulou K, Kosmidis S, Grammenoudi S, Skoulakis EM, Phosphorylation differentiates tau-dependent neuronal toxicity and dysfunction. Biochem Soc Trans. 2010;38(4):981–7. doi: 10.1042/BST038098120658989
74. Perez M, Hernandez F, Gomez-Ramos A, Smith M, Perry G, Avila J, Formation of aberrant phosphotau fibrillar polymers in neural cultured cells. European journal of biochemistry / FEBS. 2002;269(5):1484–9. 11874463
75. Terwel D, Muyllaert D, Dewachter I, Borghgraef P, Croes S, Devijver H, et al. Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice. Am J Pathol. 2008;172(3):786–98. doi: 10.2353/ajpath.2008.07090418258852
76. Bourouis M, Targeted increase in shaggy activity levels blocks wingless signaling. Genesis. 2002;34(1–2):99–102. 12324959
77. Wang JZ, Gong CX, Zaidi T, Grundke-Iqbal I, Iqbal K, Dephosphorylation of Alzheimer paired helical filaments by protein phosphatase-2A and -2B. J Biol Chem. 1995;270(9):4854–60. 7876258
78. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT, Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 2002;103(1):26–35. Epub 2002/02/12. 11837744
79. Dickey CA, Dunmore J, Lu B, Wang JW, Lee WC, Kamal A, et al. HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB J. 2006;20(6):753–5. Epub 2006/02/09. 16464956
80. Wang Y, Martinez-Vicente M, Kruger U, Kaushik S, Wong E, Mandelkow EM, et al. Synergy and antagonism of macroautophagy and chaperone-mediated autophagy in a cell model of pathological tau aggregation. Autophagy. 2010;6(1):182–3. 20023429
81. Dolan PJ, Jin YN, Hwang W, Johnson GV, Decreases in valosin-containing protein result in increased levels of tau phosphorylated at Ser262/356. FEBS Lett. 2011;585(21):3424–9. doi: 10.1016/j.febslet.2011.09.03221983102
82. Hamano T, Gendron TF, Causevic E, Yen SH, Lin WL, Isidoro C, et al. Autophagic-lysosomal perturbation enhances tau aggregation in transfectants with induced wild-type tau expression. Eur J Neurosci. 2008;27(5):1119–30. doi: 10.1111/j.1460-9568.2008.06084.x18294209
83. Berger Z, Ravikumar B, Menzies FM, Oroz LG, Underwood BR, Pangalos MN, et al. Rapamycin alleviates toxicity of different aggregate-prone proteins. Human Molecular Genetics. 2006;15(3):433–42. 16368705
84. Jo C, Gundemir S, Pritchard S, Jin YN, Rahman I, Johnson GV, Nrf2 reduces levels of phosphorylated tau protein by inducing autophagy adaptor protein NDP52. Nature communications. 2014;5:3496. doi: 10.1038/ncomms449624667209
85. Nixon RA, Autophagy, amyloidogenesis and Alzheimer disease. J Cell Sci. 2007;120(Pt 23):4081–91. 18032783
86. Inoue K, Rispoli J, Kaphzan H, Klann E, Chen EI, Kim J, et al. Macroautophagy deficiency mediates age-dependent neurodegeneration through a phospho-tau pathway. Mol Neurodegener. 2012;7:48. doi: 10.1186/1750-1326-7-4822998728
87. Moreau K, Fleming A, Imarisio S, Lopez Ramirez A, Mercer JL, Jimenez-Sanchez M, et al. PICALM modulates autophagy activity and tau accumulation. Nature communications. 2014;5:4998. doi: 10.1038/ncomms599825241929
88. Cataldo AM, Barnett JL, Berman SA, Li J, Quarless S, Bursztajn S, et al. Gene expression and cellular content of cathepsin D in Alzheimer's disease brain: evidence for early up-regulation of the endosomal-lysosomal system. Neuron. 1995;14(3):671–80. 7695914
89. Luna-Munoz J, Chavez-Macias L, Garcia-Sierra F, Mena R, Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer's disease. J Alzheimers Dis. 2007;12(4):365–75. 18198423
90. Cho JH, Johnson GV, Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize microtubules. J Neurochem. 2004;88(2):349–58. 14690523
91. Green KN, Steffan JS, Martinez-Coria H, Sun X, Schreiber SS, Thompson LM, et al. Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci. 2008;28(45):11500–10. doi: 10.1523/JNEUROSCI.3203-08.200818987186
92. Kondo A, Shahpasand K, Mannix R, Qiu J, Moncaster J, Chen CH, et al. Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature. 2015;523(7561):431–6. doi: 10.1038/nature1465826176913
93. Nakamura K, Greenwood A, Binder L, Bigio EH, Denial S, Nicholson L, et al. Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer's disease. Cell. 2012;149(1):232–44. doi: 10.1016/j.cell.2012.02.01622464332
94. Liou YC, Sun A, Ryo A, Zhou XZ, Yu ZX, Huang HK, et al. Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature. 2003;424(6948):556–61. 12891359
95. Sengupta A, Kabat J, Novak M, Wu Q, Grundke-Iqbal I, Iqbal K, Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch Biochem Biophys. 1998;357(2):299–309. 9735171
96. Alonso AD, Di Clerico J, Li B, Corbo CP, Alaniz ME, Grundke-Iqbal I, et al. Phosphorylation of tau at Thr212, Thr231, and Ser262 combined causes neurodegeneration. J Biol Chem. 2010;285(40):30851–60. Epub 2010/07/29. doi: 10.1074/jbc.M110.11095720663882
97. Beharry C, Alaniz ME, Alonso Adel C, Expression of Alzheimer-like pathological human tau induces a behavioral motor and olfactory learning deficit in Drosophila melanogaster. J Alzheimers Dis. 2013;37(3):539–50. doi: 10.3233/JAD-13061723948901
98. Bi M, Ittner A, Ke YD, Gotz J, Ittner LM, Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One. 2011;6(12):e26860. doi: 10.1371/journal.pone.002686022174735
99. Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H, Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol. 2010;224(2):472–85. doi: 10.1016/j.expneurol.2010.05.01020546729
100. Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, Zommer N, et al. Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res. 2012;9(4):397–405. 22272619
101. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM, Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem. 2011;118(4):658–67. doi: 10.1111/j.1471-4159.2011.07337.x21644996
102. Boutajangout A, Quartermain D, Sigurdsson EM, Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci. 2010;30(49):16559–66. doi: 10.1523/JNEUROSCI.4363-10.201021147995
103. Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Lasagna-Reeves CA, Gerson JE, Singh G, et al. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci. 2014;34(12):4260–72. doi: 10.1523/JNEUROSCI.3192-13.201424647946
104. Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, et al. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem. 2011;286(39):34457–67. doi: 10.1074/jbc.M111.22963321841002
105. Umeda T, Eguchi H, Kunori Y, Matsumoto Y, Taniguchi T, Mori H, et al. Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice. Ann Clin Transl Neurol. 2015;2(3):241–55. doi: 10.1002/acn3.17125815351
106. Yanamandra K, Jiang H, Mahan TE, Maloney SE, Wozniak DF, Diamond MI, et al. Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann Clin Transl Neurol. 2015;2(3):278–88. doi: 10.1002/acn3.17625815354
107. Mazanetz MP, Fischer PM, Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nature reviews Drug discovery. 2007;6(6):464–79. 17541419
108. Bulic B, Pickhardt M, Mandelkow E, Progress and developments in tau aggregation inhibitors for Alzheimer disease. J Med Chem. 2013;56(11):4135–55. doi: 10.1021/jm301731723484434
109. Medina DX, Caccamo A, Oddo S, Methylene blue reduces abeta levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol. 2011;21(2):140–9. doi: 10.1111/j.1750-3639.2010.00430.x20731659
110. Hochgrafe K, Sydow A, Matenia D, Cadinu D, Konen S, Petrova O, et al. Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau. Acta Neuropathol Commun. 2015;3:25. doi: 10.1186/s40478-015-0204-425958115
111. van Bebber F, Paquet D, Hruscha A, Schmid B, Haass C, Methylene blue fails to inhibit Tau and polyglutamine protein dependent toxicity in zebrafish. Neurobiol Dis. 2010;39(3):265–71. doi: 10.1016/j.nbd.2010.03.02320381619
112. Lee S, Wang JW, Yu W, Lu B, Phospho-dependent ubiquitination and degradation of PAR-1 regulates synaptic morphology and tau-mediated Abeta toxicity in Drosophila. Nature communications. 2012;3:1312. doi: 10.1038/ncomms227823271647
113. Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li A, et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron. 2014;82(6):1271–88. doi: 10.1016/j.neuron.2014.04.04724857020
114. Iijima K, Chiang HC, Hearn SA, Hakker I, Gatt A, Shenton C, et al. Abeta42 mutants with different aggregation profiles induce distinct pathologies in Drosophila. PLoS One. 2008;3(2):e1703. Epub 2008/02/28. doi: 10.1371/journal.pone.000170318301778
115. Wang JW, Imai Y, Lu B, Activation of PAR-1 kinase and stimulation of tau phosphorylation by diverse signals require the tumor suppressor protein LKB1. J Neurosci. 2007;27(3):574–81. Epub 2007/01/20. 17234589
116. Ueno H, Murayama O, Maeda S, Sahara N, Park JM, Murayama M, et al. Novel conformation-sensitive antibodies specific to three- and four-repeat tau. Biochem Biophys Res Commun. 2007;358(2):602–7. 17493585